FDA Likely To Take Holistic View Of AER Bill Compliance, Expert Says
This article was originally published in The Tan Sheet
Executive Summary
FDA will likely evaluate a company's compliance with adverse event reporting and record-keeping requirements on a "performance-oriented basis," said Rick Kingston, PharmD, president and senior clinical toxicologist at SafetyCall International, an adverse event call center